AbbVie vs Eli Lilly

AbbVie (ABBV), health care, and Eli Lilly (LLY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and AbbVie $518.6B: Eli Lilly is valued at 2.4 times as much. AbbVie trades at 50.5 times earnings and Eli Lilly at 45.9. Over the past year AbbVie's share price has moved +25.9% and Eli Lilly's +39.0%.

Key facts

AbbVie market value
$518.6B
Eli Lilly market value
$1.26T
AbbVie P/E
50.5
Eli Lilly P/E
45.9
AbbVie revenue
$61.2BFY to 2025-12-31
Eli Lilly revenue
$65.2BFY to 2025-12-31
Superinvestors holding both
11

Market values as of .

AbbVie vs Eli Lilly: every measure side by side
Measure AbbVie Eli Lilly
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$518.6Blower$1.26Thigher
Revenue$61.2Blower$65.2Bhigher
Earnings$4.2Blower$20.6Bhigher
Employees57,000higher50,000lower
Total assets$134Bhigher$112.5Blower
Valuation
P/E50.5higher45.9lower
P/S8.5lower19.3higher
P/B—31.3
Dividend yield2.35%higher0.47%lower
Profitability
Operating margin24.6%—
Balance sheet
Net assets-$3.3Blower$26.5Bhigher
Total liabilities$137.2Bhigher$85.9Blower
Total debt$67.5Bhigher$42.5Blower
Cash on hand$5.2Blower$7.3Bhigher
Price change
Today-0.39%higher-1.22%lower
1 year+25.9%lower+39.0%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Eli Lilly). Who owns ABBV · Who owns LLY

Further comparisons

Learn

Questions and answers

Which is bigger, AbbVie or Eli Lilly?

By market value, Eli Lilly is the larger: $1.26T against $518.6B for AbbVie. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $61.2B for AbbVie.

Which has the higher P/E ratio?

AbbVie: 50.5, against 45.9 for Eli Lilly. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

AbbVie: 2.35%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

AbbVie: $67.5B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AbbVie and Eli Lilly?

In their latest 13F filings, Ken Fisher, Larry Robbins, Ken Griffin, David Shaw (founder), Israel Englander, Cliff Asness, Mairs & Power team, Jensen team, Murray Stahl, Rajiv Jain and Bill Nygren hold both.

Cite this page

Funkfolio, “AbbVie vs Eli Lilly”, data as of 17 November 2026. https://funkfolio.com/compare/abbv-vs-lly

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.